EcoDrugPlus

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOMEG00000013105
Gene Symbol: PSMC2
3 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOMEG00000005432
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSOMEG00000005164
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSOMEG00000022697
Gene Symbol: PSMC5
3 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSOMEG00000012055
Gene Symbol: PSMC6
3 Cross references
242 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOMEG00000022029
Gene Symbol: PSMD1
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSOMEG00000004102
Gene Symbol: PSMD11
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSOMEG00000008610
Gene Symbol: PSMD12
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSOMEG00000011614
Gene Symbol: PSMD13
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSOMEG00000014614
Gene Symbol: PSMD14
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSOMEG00000019456
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSOMEG00000009462
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).